NMPA accepts Overland ADCT BioPharma’s BLA for ZYNLONTA
Overland ADCT BioPharma is a joint venture between Overland Pharmaceuticals and ADC Therapeutics. This therapy is seeking an indication to treat adults with relapsed or refractory (r/r) diffuse
Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024.
The US products are FLAREX, NATACYN, TOBRADEX, VERKAZIA, ZERVIATE, FRESHKOTE, while the Canadian products are VERKAZIA, Cationorm PLUS. FLAREX (fluorometholone acetate ophthalmic suspension) is indicated for treating steroid-responsive
Under the collaboration, the companies will leverage Eleven’s DELiveri platform that uses DNA-encoded libraries (DELs), for identifying new molecules that promote precise nucleic acid delivery for treating cardiometabolic